secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001193125-25-179817
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q2 revenue $15.3M beats consensus; net loss narrows to $13.3M from $22.8M YoY
--------------------------------------------------------------------------------

- Revenue $15.3M, beating $14.1M analyst consensus; net loss $13.3M ($0.16/sh) vs $22.8M ($0.32/sh) YoY.
- Product gross margin improved to 72% from 45% YoY on shift to more profitable products.
- Raised $27.3M via ATM and Innovatus loan; cash and investments balance $66.3M at Q2 end.
- ECO Synthesis platform: over 30 opportunities, 6 presentations at TIDES USA, 3 CDMO collaborations.
- Appointed Cynthia Collins (CEO of Nutcracker Therapeutics) to Board of Directors in April 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000119312525179817/0001193125-25-179817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000119312525179817/d940510d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-179817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer